Details

Autor(en) / Beteiligte

• Riedel, Fabian
• Hoffmann, Ann Sophie
• Moderow, Mareike
• Heublein, Sabine
• Deutsch, Thomas M.
• Golatta, Michael
• Wallwiener, Markus
• Schneeweiss, Andreas
• Heil, Joerg
• Hennigs, André

Titel

Time trends of neoadjuvant chemotherapy for early breast cancer

Ist Teil von

• International journal of cancer, 2020-12, Vol.147 (11), p.3049-3058

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2020

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Neoadjuvant chemotherapy (NACT) in early breast cancer (EBC) enables in vivo sensitivity testing and less radical surgery as compared to primary surgery and adjuvant chemotherapy (ACT). The aim of our study is to illustrate trends of systemic treatment of EBC. The study analyzed chemotherapy usage and time trends for patients with EBC treated at 104 German breast units between January 2008 and December 2017. The data were obtained through a quality‐controlled benchmarking process. Altogether, 124 084 patients were included, of whom 46 279 (37.3%) received chemotherapy. For 44 765 of these cases, detailed information on systemic treatment and surgery were available. Overall use of chemotherapy declined from 42.0% in 2008 to 32.0% in 2017. During that same time, the proportion of NACT increased from 20.0% to 57.7%, irrespective of tumor subtype. The pathological complete response (pCR) rate (defined as ypT0 ypN0) at surgery after NACT increased from 15.0% to 34.2%. The results from this large cohort from the clinical routine reflect the refined indications for chemotherapy in EBC. What's new? During the last decade, neoadjuvant chemotherapy of early breast cancer evolved from a therapy intended to enable operability to a standard treatment option enabling in vivo sensitivity testing. To date, there is only limited data on the use of chemotherapy in routine cohorts, however. Here, the authors analyze recent time trends on chemotherapy indications and applications as well as pathological complete response rates based on 124,084 patients treated at 104 breast care centers in Germany between 2008 and 2017. These results reflect today's refined, more individualized indications for chemotherapy in routine clinical practice and its preferred application as neoadjuvant chemotherapy.